Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis

Hironori Nagasaka, Tohru Yorifuji, Kenichi Hirano, Akemi Ota, Yumiko Toyama-Nakagawa, Tomozumi Takatani, Hirokazu Tsukahara, Kunihiko Kobayashi, Masaki Takayanagi, Yukihiro Inomata, Shinji Uemoto, Takashi Miida

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

No appropriate pharmaceutical therapy has been established for dyslipidemia with cholestasis in progressive familial intrahepatic cholestasis (PFIC)-1. We evaluated the efficacy of bezafibrate in PFIC-1. We monitored the clinical presentation and lipoprotein metabolism of 3 patients, aged 3, 4, and 8 years, with FIC1 deficiency, manifesting PFIC-1, over 12 months of bezafibrate therapy. Pruritus was substantially alleviated in the 3 patients after initiation of bezafibrate. Cholestasis was alleviated in 2 of them. Serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol increased 1.6- to 2.0-fold and 1.1- to 1.2-fold, respectively; but the values remained low and normal, respectively. Serum lipoprotein X, which was at normal levels before treatment, was elevated to levels above the upper limit of the reference range. High serum triglyceride levels decreased by 15% to 30%, to normal levels, after treatment initiation. The activities of lipoprotein lipase and hepatic triglyceride lipase were increased, but those of high-density lipoprotein regulators remained unchanged. Liver expression of multidrug resistance protein-3, which regulates lipoprotein X synthesis, was enhanced by bezafibrate therapy. Bezafibrate treatment favorably affected pruritus, dyslipidemia, and cholestasis in PFIC-1.

Original languageEnglish
Pages (from-to)48-54
Number of pages7
JournalMetabolism: Clinical and Experimental
Volume58
Issue number1
DOIs
Publication statusPublished - Jan 2009
Externally publishedYes

Fingerprint

Bezafibrate
Intrahepatic Cholestasis
Cholestasis
Dyslipidemias
Lipoprotein-X
Pruritus
Therapeutics
Serum
Lipoprotein Lipase
Liver
HDL Lipoproteins
Lipase
LDL Cholesterol
HDL Cholesterol
Lipoproteins
Progressive familial intrahepatic 1 Cholestasis
Reference Values
Triglycerides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis. / Nagasaka, Hironori; Yorifuji, Tohru; Hirano, Kenichi; Ota, Akemi; Toyama-Nakagawa, Yumiko; Takatani, Tomozumi; Tsukahara, Hirokazu; Kobayashi, Kunihiko; Takayanagi, Masaki; Inomata, Yukihiro; Uemoto, Shinji; Miida, Takashi.

In: Metabolism: Clinical and Experimental, Vol. 58, No. 1, 01.2009, p. 48-54.

Research output: Contribution to journalArticle

Nagasaka, Hironori ; Yorifuji, Tohru ; Hirano, Kenichi ; Ota, Akemi ; Toyama-Nakagawa, Yumiko ; Takatani, Tomozumi ; Tsukahara, Hirokazu ; Kobayashi, Kunihiko ; Takayanagi, Masaki ; Inomata, Yukihiro ; Uemoto, Shinji ; Miida, Takashi. / Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis. In: Metabolism: Clinical and Experimental. 2009 ; Vol. 58, No. 1. pp. 48-54.
@article{b55771aeae2d4d02ac010e159b570b5e,
title = "Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis",
abstract = "No appropriate pharmaceutical therapy has been established for dyslipidemia with cholestasis in progressive familial intrahepatic cholestasis (PFIC)-1. We evaluated the efficacy of bezafibrate in PFIC-1. We monitored the clinical presentation and lipoprotein metabolism of 3 patients, aged 3, 4, and 8 years, with FIC1 deficiency, manifesting PFIC-1, over 12 months of bezafibrate therapy. Pruritus was substantially alleviated in the 3 patients after initiation of bezafibrate. Cholestasis was alleviated in 2 of them. Serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol increased 1.6- to 2.0-fold and 1.1- to 1.2-fold, respectively; but the values remained low and normal, respectively. Serum lipoprotein X, which was at normal levels before treatment, was elevated to levels above the upper limit of the reference range. High serum triglyceride levels decreased by 15{\%} to 30{\%}, to normal levels, after treatment initiation. The activities of lipoprotein lipase and hepatic triglyceride lipase were increased, but those of high-density lipoprotein regulators remained unchanged. Liver expression of multidrug resistance protein-3, which regulates lipoprotein X synthesis, was enhanced by bezafibrate therapy. Bezafibrate treatment favorably affected pruritus, dyslipidemia, and cholestasis in PFIC-1.",
author = "Hironori Nagasaka and Tohru Yorifuji and Kenichi Hirano and Akemi Ota and Yumiko Toyama-Nakagawa and Tomozumi Takatani and Hirokazu Tsukahara and Kunihiko Kobayashi and Masaki Takayanagi and Yukihiro Inomata and Shinji Uemoto and Takashi Miida",
year = "2009",
month = "1",
doi = "10.1016/j.metabol.2008.08.005",
language = "English",
volume = "58",
pages = "48--54",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Effects of bezafibrate on dyslipidemia with cholestasis in children with familial intrahepatic cholestasis-1 deficiency manifesting progressive familial intrahepatic cholestasis

AU - Nagasaka, Hironori

AU - Yorifuji, Tohru

AU - Hirano, Kenichi

AU - Ota, Akemi

AU - Toyama-Nakagawa, Yumiko

AU - Takatani, Tomozumi

AU - Tsukahara, Hirokazu

AU - Kobayashi, Kunihiko

AU - Takayanagi, Masaki

AU - Inomata, Yukihiro

AU - Uemoto, Shinji

AU - Miida, Takashi

PY - 2009/1

Y1 - 2009/1

N2 - No appropriate pharmaceutical therapy has been established for dyslipidemia with cholestasis in progressive familial intrahepatic cholestasis (PFIC)-1. We evaluated the efficacy of bezafibrate in PFIC-1. We monitored the clinical presentation and lipoprotein metabolism of 3 patients, aged 3, 4, and 8 years, with FIC1 deficiency, manifesting PFIC-1, over 12 months of bezafibrate therapy. Pruritus was substantially alleviated in the 3 patients after initiation of bezafibrate. Cholestasis was alleviated in 2 of them. Serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol increased 1.6- to 2.0-fold and 1.1- to 1.2-fold, respectively; but the values remained low and normal, respectively. Serum lipoprotein X, which was at normal levels before treatment, was elevated to levels above the upper limit of the reference range. High serum triglyceride levels decreased by 15% to 30%, to normal levels, after treatment initiation. The activities of lipoprotein lipase and hepatic triglyceride lipase were increased, but those of high-density lipoprotein regulators remained unchanged. Liver expression of multidrug resistance protein-3, which regulates lipoprotein X synthesis, was enhanced by bezafibrate therapy. Bezafibrate treatment favorably affected pruritus, dyslipidemia, and cholestasis in PFIC-1.

AB - No appropriate pharmaceutical therapy has been established for dyslipidemia with cholestasis in progressive familial intrahepatic cholestasis (PFIC)-1. We evaluated the efficacy of bezafibrate in PFIC-1. We monitored the clinical presentation and lipoprotein metabolism of 3 patients, aged 3, 4, and 8 years, with FIC1 deficiency, manifesting PFIC-1, over 12 months of bezafibrate therapy. Pruritus was substantially alleviated in the 3 patients after initiation of bezafibrate. Cholestasis was alleviated in 2 of them. Serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol increased 1.6- to 2.0-fold and 1.1- to 1.2-fold, respectively; but the values remained low and normal, respectively. Serum lipoprotein X, which was at normal levels before treatment, was elevated to levels above the upper limit of the reference range. High serum triglyceride levels decreased by 15% to 30%, to normal levels, after treatment initiation. The activities of lipoprotein lipase and hepatic triglyceride lipase were increased, but those of high-density lipoprotein regulators remained unchanged. Liver expression of multidrug resistance protein-3, which regulates lipoprotein X synthesis, was enhanced by bezafibrate therapy. Bezafibrate treatment favorably affected pruritus, dyslipidemia, and cholestasis in PFIC-1.

UR - http://www.scopus.com/inward/record.url?scp=57049089482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049089482&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2008.08.005

DO - 10.1016/j.metabol.2008.08.005

M3 - Article

C2 - 19059530

AN - SCOPUS:57049089482

VL - 58

SP - 48

EP - 54

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -